Milton H. Werner insider trades: Inhibikase Therapeutics (IKT) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Milton reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 16, 2022 | IKT | ↑ Buy | 5,000 | $0.80 | $4K | Direct | Aug 16, 2022 (0d) |
| May 27, 2022 | IKT | ↑ Buy | 5,000 | $0.98 | $5K | Direct | May 31, 2022 (4d) |
| May 20, 2022 | IKT | ↑ Buy | 10,000 | $0.60 | $6K | Direct | May 23, 2022 (3d) |
| Nov 17, 2021 | IKT | ↑ Buy | 23,589 | $1.97 | $47K | Domestic Partner | Nov 19, 2021 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other IKT insiders
Open-market trades in the last 12 months
About Milton H. Werner's insider trades
Milton H. Werner is President and CEO at Inhibikase Therapeutics (IKT). Since Nov 17, 2021, Milton has reported 4 open-market purchases worth $61K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (7 filings), option exercises (3 filings), shares returned to the company (1 filing), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IKT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.